We are live on ! Find out more
RCP

Remedium Capital Partners Portfolio holdings

AUM $452M
This Fund
S&P 500
This Quarter Est. Return
+67.38%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$452M
AUM Growth
+$170M
Cap. Flow
+$859K
Cap. Flow %
0.19%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$579K
2
APGE icon
Apogee Therapeutics
APGE
+$279K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORKA
1
Oruka Therapeutics
ORKA
$6.58B
$149M 32.99%
1,565,661
– –
SYRE icon
2
Spyre Therapeutics
SYRE
$8.25B
$130M 28.78%
1,464,169
+7,938
+0.5% +$579K
APGE icon
3
Apogee Therapeutics
APGE
$10.2B
$77.9M 17.24%
586,691
+3,100
+0.5% +$279K
DMRA
4
Damora Therapeutics
DMRA
$1.88B
$53.2M 11.78%
2,045,473
– –
JBIO
5
Jade Biosciences
JBIO
$1.36B
$35.1M 7.76%
1,577,750
– –
CBIO
6
Crescent Biopharma
CBIO
$669M
$6.5M 1.44%
361,250
– –

Similar funds

WC
Winmill & Co Walpole, New Hampshire $452M AUM 56.84% 1-Year Est. Return
FDS
Freedom Day Solutions Houston, Texas $452M AUM 24.78% 1-Year Est. Return
IWMA
Ironwood Wealth Management (Arizona) Chandler, Arizona $451M AUM 13.94% 1-Year Est. Return
BAMG
Brand Asset Management Group Chesterfield, Missouri $452M AUM 25.97% 1-Year Est. Return
ECM
Endure Capital Management Austin, Texas $451M AUM
BFT
Bitwise Funds Trust San Francisco, California $452M AUM
LL
LPWM LLC Minneapolis, Minnesota $451M AUM 18.82% 1-Year Est. Return
CFA
CWS Financial Advisors Kalamazoo, Michigan $451M AUM 11.68% 1-Year Est. Return

Remedium Capital Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Remedium Capital Partners held 6 positions worth $452M, up 61% from $281M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2026: portfolio turnover was 0%. Remedium Capital Partners opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Remedium Capital Partners added most to Spyre Therapeutics in Q2 2026, an estimated $579K increase.
  • Remedium Capital Partners's ten largest holdings make up 100% of its $452M portfolio in Q2 2026.
  • Remedium Capital Partners opened 0 new positions and closed 0 in Q2 2026.
  • Remedium Capital Partners's portfolio value rose 61% quarter-over-quarter to $452M.

Based on Remedium Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.